Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Oct. 31, 2012		Oct. 31, 2011		Oct. 31, 2010
Revenues (1):
Product sales and revenues	$ 94,950		$ 103,007		$ 50,192
Service agreement revenues	18,183		12,097		9,034
Research and development contracts	7,470		7,466		10,551
Total revenues	120,603	[1]	122,570	[1]	69,777	[1]
Costs of revenues:
Cost of product sales	93,876		96,525		54,433
Cost of service agreement revenues	19,045		30,825		23,627
Cost of research and development contracts	7,237		7,830		10,370
Total costs of revenues	120,158		135,180		88,430
Gross profit (loss)	445		(12,610)		(18,653)
Operating expenses:
Administrative and selling expenses	18,220		16,299		17,150
Research and development expenses	14,354		16,768		18,562
Total operating expenses	32,574		33,067		35,712
Loss from operations	(32,129)		(45,677)		(54,365)
Interest expense	(2,304)		(2,578)		127
Income (loss) from equity investment	(645)		58		(730)
Impairment of equity Investment	(3,602)		0		0
License fee and royalty income	1,599		1,718		1,561
Other income (expense), net	1,244		1,047		(254)
Loss before redeemable preferred stock of subsidiary	(35,837)		(45,432)		(53,915)
Accretion of redeemable preferred stock of subsidiary	0		(525)		(2,367)
Loss before provision for income taxes	(35,837)		(45,957)		(56,282)
Provision for income taxes	(69)		(17)		(44)
Net loss	(35,906)		(45,974)		(56,326)
Net loss attributable to noncontrolling interest	411		261		663
Net loss attributable to FuelCell Energy	(35,495)		(45,713)		(55,663)
Adjustment for Modification of Redeemable Preferred Stock of Subsidiary	0		(8,987)		0
Preferred stock dividends	(3,201)		(3,200)		(3,201)
Net loss to common shareholders	$ (38,696)		$ (57,900)		$ (58,864)
Net loss to common shareholders per share
Basic	$ (0.23)		$ (0.47)		$ (0.63)
Diluted	$ (0.23)	[2]	$ (0.47)	[2]	$ (0.63)	[2]
Basic	165,471,261		124,498,073		93,925,863
Diluted	165,471,261		124,498,073		93,925,863

[1] (1) Includes revenue from a related party. Refer to Concentrations in note 1 to the financial statements.

[2] Due to the net loss to common shareholders in each of the years presented above, diluted earnings per share was computed without consideration to potentially dilutive instruments as their inclusion would have been antidilutive. Potentially dilutive instruments include stock options, warrants and convertible preferred stock. At October 31, 2012, 2011 and 2010, there were options to purchase 3.1 million, 3.3 million and 5.1 million shares of common stock, respectively. On January 13, 2011 we issued 10.2 million warrants in connection with a registered direct offering. Each warrant was exercisable for 1 share of common stock. The warrants had an exercise price of $2.29 per share and were exercisable beginning six months and one day after the initial closing date and expired in the fourth quarter of 2012.